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Abstract
The present study investigated the chronic efficacy of oleanolic acid (OA), a triterpenoid selected from our recent screening,
on hyperglycemia in type-2 diabetic mice. C57BL/6J mice were fed a high-fat diet followed by low doses of streptozotocin
to generate a type-2 diabetic model. OA (100 mg/kg/day) was administered orally for 2 weeks with its effects monitored for
6 weeks. High-fat feeding and streptozotocin generated a steady hyperglycemia (21.261.1 mM) but OA administration
reversed the hyperglycemia by ,60%. Interestingly, after the cessation of OA administration, the reversed hyperglycemia
was sustained for the entire post-treatment period of the study (4 weeks) despite the reoccurrence of dyslipidemia.
Examination of insulin secretion and pancreas morphology did not indicate improved b-cell function as a likely mechanism.
Urine glucose loss was decreased with substantial improvement of diabetic nephropathy after the OA treatment. Pair-
feeding the OA-treated mice to an untreated group ruled out food intake as a main factor attributable for this sustained
reduction in hyperglycemia. Studies with the use of glucose tracers revealed no increase in glucose influx into muscle,
adipose tissue or liver in the OA-treated mice. Finally, we analyzed key regulators of gluconeogenesis in the liver and found
significant increases in the phosphorylation of both Akt and FoxO1 after treatment with OA. Importantly, these increases
were significantly correlated with a down-regulation of glucose-6-phosphatase expression. Our findings suggest
triterpenoids are a potential source of new efficacious drugs for sustained control of hyperglycemia. The liver appears to
be a major site of action, possibly by the suppression of hepatic glucose production via the Akt/FoxO1 axis.
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Introduction
The incidence of diabetes is estimated at 220 million worldwide
[1] and prolonged hyperglycemia is a major cause of various
diabetic complications including nephropathy [2]. Effective
control of blood glucose is, therefore, crucial to the treatment of
diabetes and the prevention/delay of diabetic complications.
Type-2 diabetes accounts for ,90% of all diabetes cases [1] and it
results from the metabolic disorders of insulin resistance (dimin-
ished sensitivity of the target tissues to insulin action) and b-cell
failure (reduced ability of the pancreatic b-cells to produce
sufficient insulin). Therefore, improvements of insulin action and
b-cell function are important mechanisms for the pharmacological
treatment of type-2 diabetes.
Sustained control of hyperglycemia is of great importance to the
treatment of type-2 diabetes and it remains a significant challenge.
Until recently, the mainstay oral medications to improve insulin
action in type-2 diabetes have been biguanides (e.g.metformin)
and thiazolidinediones (TZDs) [3]. However, biguanides are not
adequate therapies on their own in the long-term [3,4] as they
have limited effects in improving insulin action in muscle [5,6].
While TZDs are effective in lowering hyperglycemia, largely by an
insulin sensitizing action [7,8], concerns over the adverse effects of
TZDs on an increased risk of heart failure [9] and bladder cancer
[10] have restricted their long-term use. Other new drugs such as
GLP analogues and inhibitors of the sodium glucose co-
transporter (SGLT) appear promising [11,12,13], however their
long term effectiveness is not clear. Thus there remains an urgent
need for the development of new anti-diabetic drugs with
sustained efficacy.
We recently found that triterpenoid compounds isolated from
bitter melon have potent efficacy in stimulating GLUT4 translo-
cation in L6 myotubes and 3T3L1 adipocytes, along with
activation of the AMPK pathway [14] Our acute studies in mice
showed that triterpenoids are able to reduce glucose intolerance in
insulin resistant high-fat (HF)-fed mice after a single injection [14].
These findings are encouraging because triterpenoids are a rich
natural source for drug discovery, with more than 20,000 of them
known to exist in plants [15]. The present study investigated
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whether the triterpenoid, oleanolic acid (OA), is an effective
treatment for hyperglycemia in a murine model of type-2 diabetes.
The study focused on the OA compound based on our recent
screens [14].
OA itself has been used in humans for its potential therapeutic
application for cancer [15] and an OA analogue has been shown
to alleviate diabetic nephropathy in type-2 diabetic patients [16].
OA and its analogues have been shown to lower hyperglycemia in
STZ-treated rodents [17], HF-fed or db/db mice [18], to protect
against diabetic nephropathy [17] and to enhance the survival of
pancreatic islets [19]. However, all of these studies were relatively
short-term (mostly less than 2 weeks) and the sustainability of these
therapeutic effects is not known. Here we investigated the
therapeutic efficacy of OA in reducing hyperglycemia in a murine
diabetic model produced by chronic HF feeding combined with
low doses of STZ [20,21]. We demonstrate a potent glucose-
lowering effect that was sustained well beyond the treatment
period and was accompanied by a significant improvement in
renal structures. Furthermore, we have identified Akt/FoxO1
mediated suppression of glucose-6-phosphatase (G6Pase), a key
regulator of hepatic glucose production, as a likely mechanism
underlying the improved glucose homeostasis.
Materials and Methods
Animal model
Male C57BL/6J mice (10 weeks old) were purchased from the
Animal Resources Centre (Perth, Australia). The animals were
kept in a temperature-controlled room (2261uC) on a 12-h light/
dark cycle with free access to food and water. After 1 week of
acclimatization, mice were fed ad libitum for 10 weeks with a
standard lab chow diet (CH; 8% calories from fat, 21% calories
from protein, and 71% calories from carbohydrate) or a high-fat
diet (HF; 45% calories from fat, 20% calories from protein, and
35% calories from carbohydrate) in order to induce insulin
resistance [7,8,14,22]. Mice were then injected with either vehicle
(saline) or a low dose of streptosotocin (STZ, 40 mg/kg/day) for
five consecutive days in order to induce diabetes (fasting blood
glucose .12 mM) [20,21]. CH-fed mice treated with STZ
comprised a model of type-1 diabetes (T1D mice). HF-fed mice
treated with STZ comprised a model of type-2 diabetes (T2D
mice). One week after the last STZ injection (‘baseline’), a subset of
T1D and T2D mice received OA as a food additive at
100 mg?kg21?day21 for two weeks (T1D-OA and T2D-OA
respectively). This dose of OA was selected on the basis of our
previous study [14]. The remaining T1D and T2D mice received
their normal CH or HF diet (T1D-Veh and T2D-Veh,
respectively). Body weight, food intake and fasting blood glucose
levels were monitored on a weekly basis until 4 weeks after the
cessation of OA administration. All experiments were approved by
the Animal Ethics Committees of the Garvan Institute (#0847)
and RMIT University (#1012) in accordance with the guidelines
of the National Health and Medical Research Council of
Australia.
Assessment of effects on hyperglycemia, blood insulin
level and glucose tolerance
Blood glucose levels were measured once a week after 5–7 hours
of fasting. Blood samples were collected from the tail tip and were
analyzed using a glucometer (AccuCheck II; Roche, New South
Wales, Castle Hill, Australia). Two weeks after the cessation of OA
treatment, i.p. glucose tolerance tests (ipGTT; glucose load 1 g/kg
BW) were performed in the 5–7 hours fasted state, as previously
described [22]. Briefly, blood samples were obtained from the tail
tip at 0, 15, 30 and 60 min for the measurement of blood glucose
levels and at 0, 5, 30 and 60 min for the measurement of
insulinemia (determined by radioimmunoassay; Linco/Millipore,
Billerica, MA).
Insulin secretion assays, pancreatic histology and insulin
content measurements
Islet isolation and ex vivo insulin secretion assays were performed
as previously described [23]. Mice were killed by cervical
dislocation and the pancreas was perfused with 2 ml of Liberase
(Roche, Basel, Switzerland) solution (0.25 mg/ml in Krebs-Ringer
buffer) via injection into the common bile duct. After pancreatic
digestion at 37uC, islets were purified using a Ficoll-paque (GE
Healthcare, Chalfont St. Giles, U.K.) gradient. Islets were washed
and immediately pre-incubated for 1 hr in Krebs-Ringer buffer
containing HEPES (KRBH), 0.1% BSA and 2 mM glucose.
Batches of five islets were incubated at 37uC for 1 h in 130 ml
KRBH containing 0.1% BSA and 2, 5.5, 11 or 20 mM glucose.
For the measurement of pancreatic insulin content, the pancreas
was weighed and then homogenized in ice-cold acid ethanol
Table 1. Metabolic characteristics of the type-1 and type-2 diabetes mouse models.
CH (Normal) HF (IR) CH-STZ (T1D) HF-STZ (T2D)
Body weight (g) 29.560.4 31.760.8{ 28.860.4{ 27.860.2{** #
Epi fat (% BW) 1.460.1 3.260.3{{ 1.260.1{ 1.660.1** #
Blood glucose (mM) 9.260.2 8.360.4 13.660.6{{ 17.561.2{{**#
Blood insulin (pg/ml) 367629 5036130{ 300626 301663{*
Plasma triglyceride (mM) 1.260.1 1.560.1 1.960.1{{ 2.260.2**
Liver triglyceride (mmol/g) 7.860.8 18.662.0{{ 9.460.9 19.661.1{{**##
C57BL/6J mice were fed with chow diet and injected with saline (CH) or STZ (T1D), or fed with HF diet and injected with saline (HF) or STZ (T2D). IR, insulin resistant.
Blood samples were collected from mice in the 5–6 hour fasted state. Blood glucose (n = 8–10) and insulin (n$5), and plasma triglyceride (n = 7–8) were measured as
described in the methods. Body weight, epididymal weight and liver triglycerides were measured at the end of the study (n$10). Data are expressed as means 6 SE.
{p,0.05,
{{p,0.01 vs. CH;
*p,0.05,
**p,0.01 vs. HF;
#p,0.05,
##p,0.01 vs. T1D.
doi:10.1371/journal.pone.0042115.t001
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Figure 1. Effects of OA on blood glucose, food intake and body weight in T2D and T1D mice over time. HF-fed mice with STZ injections
were treated with (T2D-OA) or without (T2D-Veh) OA in the diet for two weeks, at the end of which OA was removed from the diet. Blood glucose,
food intake and body weight were monitored between 14:00 and 16:00 once a week (A, B and C). CH-fed mice with STZ injections were treated with
(T1D-OA) or without (T1D-Veh) OA in the diet for two weeks, at the end of which OA was removed from the diet. Effects of OA on hyperglycemia in
T1D mice (D). CH, normal chow fed mice. Data are expressed as means 6 SE. { p,0.05, {{ p,0.01 vs. T2D-Veh group, n = 11–16 per group.
doi:10.1371/journal.pone.0042115.g001
Figure 2. Effects of OA on glucose tolerance and blood insulin. Studies were performed in mice two weeks after the removal of OA. ipGTT
was performed with an injection of glucose (1 g/kg, ip) after 5–7 hours of fasting. Blood glucose was monitored at 0, 15, 30, and 60 min following the
glucose injection (A). ipGTT results were quantified by calculating the area under the blood glucose curve (AUC) and the incremental AUC (iAUC) (B).
Insulin levels throughout the ipGTT (C). The average value of blood insulin levels from 5 to 60 mins during the ipGTT (D). CH, normal chow fed mice;
T2D-Veh, HF-fed mice with STZ injections; T2D-OA, HF-fed mice with STZ injections and OA treatment. ** p,0.01 vs. CH; {{ p,0.01 vs. T2D-Veh,
n = 5–8 per group.
doi:10.1371/journal.pone.0042115.g002
Sustained Efficacy of Triterpenoids on Diabetes
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e42115
(0.15 M HCl in 75% ethanol) immediately after collection. Insulin
concentrations in the incubation medium and pancreatic extracts
were determined by a commercial insulin radioimmunoassay kit
(Linco/Millipore, Billerica, MA).
Quantification of b-cell area was performed based on previous
methods [24]. Each pancreas was removed, cleared of fat and
lymph nodes, fixed in 10% neutral buffered formalin and
embedded in paraffin wax. 5 mm sections were cut and incubated
for 30 min at room temperature with blocking solution (PBS
buffer with 2% BSA and 5% chick serum) before incubation
overnight at 4uC in blocking solution containing mouse anti-
insulin antibody (I2018, Sigma-Aldrich). Sections were then
incubated with chicken anti-mouse IgG-Alexa Fluor 594 conjugate
(Invitrogen) for 1 hr at room temperature in darkness. Transmit-
ted light images were captured (magnification620). To quantitate
b-cell area, the outline of the pancreas section and all insulin-
positive cells were traced and scored using ImageJ image analysis
software (ImageJ, NIH, Bethesda, MD). Results are expressed as
the percentage of the total pancreatic area stained positive for
insulin.
Assessment of the effects on urine glucose secretion and
kidney morphology
Urine samples were collected in the morning three weeks after
the completion of OA treatment. The urinary glucose level was
measured by the glucose oxidase assay using an automated glucose
analyser (YSI 2300 Stat Plus, Yellow Springs Instruments, Yellow
Springs, Ohio, USA). For the kidney morphology study, kidneys
were rapidly removed after cervical dislocation. Coronal sections
of renal tissue were immersion-fixed in 10% neutral buffered
formalin and embedded in paraffin. Sections 5 mm thick were
stained with periodic acid-Schiff and evaluated using methods
described previously [25]. To quantitate tubular atrophy, the
tubule cell height of an individual cortical tubule was measured
using line morphometry (magnification6200) by ImageJ. A total
of 50 randomly-selected cortical tubules in 10 non-overlapping
fields (magnification6200) were measured, and the mean cross-
sectional tubule cell height was determined for each section. The
degree of glomerular hypertrophy was measured quantitatively.
The outline of the glomeruli and glomerular capillary tuft was
traced, and the computed area was used as a measure of total
glomerular area and tuft area. The mean value of 20 randomly
selected glomeruli was determined for each section. The cortical
interstitial volume included the tubular basement membrane and
peritubular capillaries. To quantitate this area, cortical fields
(magnification6200) were viewed on a video screen, and the area
of interstitial space was determined with image analysis software
and expressed as a percentage of the total area of the field. The
mean percentage area of five non-overlapping cortical fields was
calculated for each section.
Measurement of plasma and liver triglyceride
Plasma was extracted from blood samples collected from the tail
tip and stored at 280uC. Mice were killed by cervical dislocation
in the fasted state and liver samples were immediately freeze-
clamped. Liver triglycerides were extracted by the method of
Folch. The triglyceride level in plasma and liver extract was
determined by a Peridochrom triglyceride GPO-PAP kit (Roche
Diagnostics) as previously described [7,8,12,22].
Measurement of glucose flux in key tissues for glucose
homeostasis
In one subset of mice, [3H] labeled 2-deoxy-D-glucose (2DG;
PerkinElmer, USA) and D-[14C] glucose (PerkinElmer, USA.)
were used to measure glucose metabolism in skeletal muscle, fat
and liver, as described in our previous work [8]. Briefly, 4 weeks
after the cessation of OA treatment, an ipGTT was performed
after 5–7 hours of fasting. Glucose (1 g/kg BW) containing [3H]-
2DG (65 mCi/kg BW) and D-[14C] glucose (32 mCi/kg BW) was
injected ip. Plasma samples were obtained from the tail tip at 10,
20, 30 and 40 min after glucose administration for estimation of
plasma tracer concentration. At the completion of the ipGTT,
mice were culled and tissue samples were immediately freeze-
clamped for subsequent analysis.
Analysis of gene expression
Total RNA was extracted from liver tissue using TRIZOLH
(Invitrogen, USA) according to the manufacturer’s instructions.
Reverse transcription was carried out with 0.2 mg of RNA using
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, USA). Real time PCR was carried out using the IQ
SYBR Green Supermix (26) (Bio-Rad Laboratories Inc, USA) for
G6Pase and PEPCK (Genework, Australia). The gene expression
Figure 3. Effects of OA on insulin secretion and insulin in
pancreatic b-cells. Four weeks after the cessation of OA treatment,
fresh islets were isolated from T2D mice treated with or without OA,
and insulin secretion in response to different glucose concentrations
was measured (A). Pancreatic insulin content (B). b-cell area (expressed
as a percentage of pancreatic area) (C). Representative images of
immunohistochemical staining of b-cells (D). T2D, HF-fed mice with STZ
injections; T2D-OA, HF-fed mice with STZ injections and OA treatment.
n = 4–6 per group.
doi:10.1371/journal.pone.0042115.g003
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from each sample was analyzed in duplicate and normalized
against the housekeeper, 18S. The primer sequence (59 to 39) of
18S was: CGCCGCTAGAGGTGAAATTCT (sense) and
CGAACCTCCGACTTTCGTTCT (antisense); PEPCK: CCA-
CAGCTGCTGCAGAACA (sense) and GAAGGGTCG-
CATGGCAAA (antisense); G6Pase: AACGCCTTC-
TATGTCCT CTTTC (sense) and GTTGCTGTAGTA-
GTCGGTGTCC (antisense). All reactions were performed on
the iQTM 5 Real Time PCR Detection System (Bio-Rad
Laboratories Inc, USA). The results are expressed as relative gene
expression using the DCt method.
Western blotting
Western blotting in liver samples was performed as described
previously [26] with minor modifications. Briefly, the freeze-
clamped liver tissues were homogenized in ice-cold lysis buffer at
pH 7.5 containing (in mM): 50 Tris, 150 NaCl, 1% Triton X-100,
10 NaP, 100 NaF, 2 Na3VO4, 1 EDTA, 1 EGTA and 10%
glycerol supplemented with protease inhibitor cocktail tablets
(Roche Diagnostics Pty Ltd, Australia) and DL-dithiothreitol.
Total protein concentrations were assessed using Bio-Rad Protein
Assay (Bio-Rad Laboratories, Hercules, CA) before protein
samples were denatured in SDS sample buffer (125 mM Tris-
HCl, pH 6.8, 50% glycerol, 2% SDS, 5% b-mercaptoethanol and
0.01% bromophenol blue). Regulation of glucoenogenesis was
assessed by total- and phospho(Ser473)-Akt, as well as total- and
phospho(Ser256)-Forkhead box protein O1 (FoxO1, Cell Signal-
ing, USA). Densitometry analysis was performed using Image Lab
software (Bio-Rad Laboratories, USA) and representative blots are
shown.
Statistical Analyses
Data are presented as means 6 SE. One-way analysis of
variance was used for comparison of relevant groups. When
significant variations were found, the Tukey-Kramer multiple
comparisons test was applied. Pearson’s two-sided correlation was
used for the correlation analysis. Differences at p,0.05 were
considered to be statistically significant.
Results
Induction of type-1 and type-2 diabetes
We first induced a type 2 diabetes model of hyperglycemia by
chronic HF-feeding and low-dose STZ based on previous reports
[20,21]. As shown in Table 1, HF feeding caused a small increase
in body weight and a 2.3 fold increase in epididymal fat compared
to CH mice. HF mice also exhibited increased blood insulin
(,40%) and liver triglyceride (2.4 fold) compared to CH mice, but
the circulating levels of glucose and triglyceride were similar
between HF and CH mice. CH-fed mice treated with STZ (T1D
thereafter), demonstrated moderate increases in blood glucose and
plasma triglyceride compared to CH mice (,50–60%, p,0.05 vs.
CH-fed mice), but liver triglyceride content was unchanged. As
expected, HF-STZ (T2D thereafter) mice recapitulated several
Figure 4. Effects of OA on glucose levels in urine and kidney morphology. Urine glucose levels in CH, T2D-Veh and T2D-OA mice were
measured before the OA treatment began and at the end of the study (4 weeks after cessation of OA treatment) (A). Kidneys were harvested and
coronal sections of renal tissues were stained with periodic acid-Schiff for the quantification of interstitial volume, glomerular tuft area and tubular
cell height (B). Representative images of stained kidney sections (C). T2D-Veh, HF-fed mice with STZ injections; T2D-OA, HF-fed mice with STZ
injections and OA treatment. * p,0.05, ** p,0.01 vs. CH; {{ p,0.01 vs. T2D-Veh, n = 5–10 per group.
doi:10.1371/journal.pone.0042115.g004
Sustained Efficacy of Triterpenoids on Diabetes
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major characteristic metabolic disorders in type-2 diabetes, namely
hyperglycemia (,2 fold), hypoinsulinemia (by 20%), dyslipidemia
(80%) and liver steatosis (2.5 fold) compared to CH mice.
Consistent with previous reports [21], T2D mice also displayed
a lack of glucose response to insulin action during an insulin
tolerance test - a typical feature of insulin resistance (data not
shown). Compared with HF feeding alone, T2D mice displayed
hyperglycemia (.2 fold, p,0.01), hypertriglyceridemia (50%,
p,0.05) and reduced plasma insulin level (50%, p,0.01) while
retaining a similar level of liver steatosis. Compared with T1D,
T2D mice showed more epididymal fat (30%), greater hypergly-
cemia (,30%) and significantly increased triglyceride content in
the liver (2 fold).
Effects of OA on hyperglycemia and glucose tolerance
Oral administration of OA, at a dose of 100 mg/kg/day,
dramatically reversed the hyperglycemia of T2D mice by more
than 60% (approaching the level of CH-fed mice) by the end of the
two-week treatment (22.560.6 vs. 13.261.9 mM, p,0.001).
Intriguingly, following the removal of OA from the HF diet, the
reversed hyperglycemia evident in the T2D-OA group persisted
for the rest of the study. Meanwhile the hyperglycemia in the
untreated T2D-Veh group remained high (Fig. 1A). Under a
similar treatment regime, OA showed no significant effect in
lowering the hyperglycemia evident in the T1D Figmouse model
(Fig. 1D). Along with a reduced food intake at the end of the two-
week treatment (Fig. 1B), T2D-OA group had a lower body weight
than T2D-Veh group at week 3 and 4 (Fig. 1C). However, food
intake and body weight of T2D-OA mice was completely
recovered by the end of the study (Fig. 1, B and C).
As the anti-hyperglycemic effect of OA was only observed in
T2D mice, our subsequent studies were performed only in the
T2D mouse model. OA significantly improved the glucose
tolerance of T2D mice as evidenced by decreased blood glucose
level in T2D-OA compared to T2D-Veh at all time points
(p,0.01) during the ipGTT as well as by a reduced area under the
curve (Fig. 2, A and B). However, when expressed as the
incremental area under the curve, we did not find a significant
difference between the T2D-Veh and T2D-OA groups. During
the ipGTT, blood insulin levels were significantly higher in T2D-
OA compared to T2D-Veh mice at 30 min, with a similar trend at
5 min (p= 0.082) (Fig. 2C). However, when expressed as the
average value from 5 to 60 min, there was no statistical difference
between the T2D-Veh and T2D-OA groups (p = 0.053, Fig. 2D).
Insulin secretion, b-cell numbers and pancreatic insulin
content post-OA treatment
Fig. 2C and D appeared to indicate a seeming improvement in
b-cell function after treatment of T2D mice with OA, which could
provide a mechanism for the improved blood glucose levels in
these mice. We therefore further assessed glucose-stimulated
insulin secretion in isolated islets. As shown in Fig. 3A, islets
isolated from T2D-OA mice showed an insulin secretion response
to increasing glucose stimulation that was indistinguishable from
T2D-Veh mice. We next examined total pancreatic insulin level
and found that the administration of OA had no effect on the total
pancreatic insulin content in T2D mice (29.1610.6 vs.
26.666.0 mg/g pancreas in the T2D-Veh group, p.0.05)
(Fig. 3B). Finally, immunohistochemical staining of pancreatic
sections showed that OA did not affect the total number of b-cells
per pancreas in T2D mice (0.2960.11% vs. 0.2760.11%,
p= 0.894) (Fig. 3C and D).
Alleviation of glucose loss in urine and nephropathy
post-OA treatment
In order to investigate if the reduced blood glucose level in
T2D-OA mice was due to an increase in the urine excretion of
glucose, we measured the glucose level in the urine of T2D mice
before and after the treatment with OA. TZD mice excreted more
glucose in the urine compared to CH-fed mice at baseline (Fig. 4A).
Whilst glucose excretion remained high in T2D mice when
measured 3 weeks after the cessation of OA treatment, TZD-OA
mice demonstrated a significant drop in urine glucose levels
(11.861.2 vs. 5.160.8 mM before vs. after OA treatment,
p,0.01) (Fig. 4A). Morphology studies revealed that the OA
treatment dramatically improved kidney structure of T2D mice, as
indicated by significant reductions in interstitial volume (13.260.7
vs. 24.960.8% in untreated T2D, p,0.01) and glomerular turf
area in T2D-OA mice (3251641 vs. 4248683 um2 in untreated
T2D-, p,0.01) to levels similar to CH-fed mice (Fig. 4B,C).
Associated with the normalization of interstitial volume and
glomerular turf area, the reduced tubular cell height evident in
T2D mice was significantly ameliorated in T2D-OA mice
(13.660.1 vs. 12.460.1 mm in untreated T2D, p,0.01) (Fig. 4B
and C).
Triglyceride levels in plasma and liver during and after
OA treatment
T2D-Veh mice had significantly higher levels of plasma and
liver triglyceride compared to CH-fed mice at the end of the two-
week treatment period (Fig. 5A) and at 4-weeks post-treatment
(Fig. 5B). As expected, two weeks of OA treatment substantially
reduced the triglyceride levels in plasma (Fig. 5A) and liver (Fig. 5B)
of T2D mice. However, 4-weeks after the termination of OA
administration, both plasma and liver triglycerides had returned to
the levels of the T2D-Veh group (Fig. 5A, B).
Figure 5. Effects of OA on triglyceride levels in plasma and liver
during and after OA treatment. Lipid accumulation in the liver and
plasma was assessed both during OA treatment (at week 2) and 4
weeks after the cessation of OA treatment. Mice were euthanized
following a 5–7 hour fast and samples of plasma (A) and liver (B) were
collected for the measurement of triglyceride levels. T2D-Veh, HF-fed
mice with STZ injections; T2D-OA, HF-fed mice with STZ injections and
OA treatment. ** p,0.01 vs. CH; {{ p,0.01 vs. T2D-Veh, n = 5–8 per
group.
doi:10.1371/journal.pone.0042115.g005
Sustained Efficacy of Triterpenoids on Diabetes
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Influence of pair-feeding on hyperglycemia and glucose
tolerance
Since a fluctuation in food intake was observed in the T2D-OA
group during the initial experiment, we carried out an additional
pair-feeding study to determine if the sustained reversal of
hyperglycemia during the period of post-OA treatment was due
to the difference in food intake. The food intake in pair-fed T2D-
Veh and T2D-OA groups (2.760.1 vs. 2.560.1 g/mouse/day,
p.0.05) was well matched (Fig. 6A). T2D-Veh and T2D-OA
groups were not different in body weight at the baseline nor at the
end of the study (Fig. 6B). The basal blood glucose of the T2D-OA
group showed a significant decrease compared to the T2D-Veh
group after two weeks of OA treatment despite matching of food
intake, and this was maintained for 3-weeks post-treatment
(Fig. 6C). Similar to the previous observation, T2D-OA mice
were more glucose tolerant than T2D-Veh mice in the ipGTT
performed two weeks after the removal of OA (Fig. 6, D and E).
Glucose flux in muscle, fat and liver after OA treatment
To further investigate the mechanism underlying the sustained
improvement in glycemia of OA treated T2D mice, we employed
[3H]-2DG and [14C]-glucose tracers to measure the glucose
uptake in muscle and adipose tissue during an ipGTT conducted 4
weeks after the cessation of OA treatment. As expected, T2D mice
demonstrated reduced glucose uptake in muscle compared to CH-
fed mice (Fig. 7A)(14.462.9 vs. 7.060.5 mmol/100 g/min,
p,0.05). A similar tendency was evident in fat tissue (7.262.3
vs. 3.360.8 mmol/100 g/min, p.0.05; Fig. 7B). However, OA
treatment of T2D mice did not cause any improvement of glucose
uptake in these two tissues (Fig. 7A, B). Furthermore, measurement
of glucose incorporation into glycogen and lipid in the liver (as a
proxy of glucose influx) did not show any improvement in T2D-
OA as compared to the T2D-Veh group (Fig. 7, C and D).
Changes in key regulators of hepatic glucose production
after OA treatment
As hepatic glucose production is a major factor affecting glucose
homeostasis [27], we investigated the key molecules (Akt and
FoxO1 [28]) in the insulin signaling pathway that regulate hepatic
gluconeogenesis and glucose production. As shown in Fig. 8A–D,
compared to CH-fed mice, T2D mice displayed a 60% reduction
of p-/t-Akt. The p-/t-Akt ratio was similar in T2D-OA and T2D-
Veh mice. However, the absolute p-Akt level was lower in T2D-
Veh mice compared to CH, but restored to CH levels in T2D-OA
Figure 6. Comparisons of blood glucose and ipGTT between pair-fed T2D-Veh and T2D-OA mice. Food intake (A), body weight (B) and
basal blood glucose (C) were monitored throughout the pair-feeding study. ipGTT was performed in mice two weeks after the cessation of OA
treatment, with an injection of glucose (1 g/kg, ip) after 5–7 hours of fasting. Blood glucose was monitored at 0, 15, 30, and 60 min following the
glucose injection (D). ipGTT results were quantified by calculating the area under the blood glucose curve (AUC) and the incremental AUC (iAUC) (E).
T2D-Veh, HF-fed mice with STZ injections; T2D-OA, HF-fed mice with STZ injections and OA treatment. { p,0.05, {{ p,0.01 vs. T2D-Veh, n = 5–10 per
group.
doi:10.1371/journal.pone.0042115.g006
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mice. In the case of FoxO1, T2D-OA mice demonstrated
substantially increased p-/t-FoxO1 (200% increase) (p,0.01)
and a 50% reduction in total FoxO1 protein compared to both
T2D-Veh and CH mice (p,0.05) (Fig. 8, A,E–G).
We next examined the transcriptional expression levels of the
key enzymes controlling gluconeogenesis (PEPCK) and glucose
production (G6Pase). As shown in Figure 9A and B, compared to
CH-fed mice, T2D mice demonstrated an elevated expression of
PEPCK (,80% increase, p,0.05) and G6Pase (,50% increase,
p.0.05) at the transcriptional level. Interestingly, treatment of
T2D mice with OA tended to reduce G6Pase RNA (,30%,
p= 0.09, Fig. 9B), while the level of PEPCK expression remained
unchanged. Further analysis showed that there was a significant
reversed correlation of both phosphorylated Akt(p,0.05) and
phosphorylated FoxO1 (p,0.05) to the transcriptional expression
level of G6Pase (Fig. 9C).
Discussion
The present study investigated the chronic effect of OA, a
triterpenoid selected from our recent screens [14], on hypergly-
cemia in diabetic mice and the contributing mechanisms involved.
Our results show that OA did not affect hyperglycemia in T1D
mice, but was able to reverse hyperglycemia in T2D mice, as
predicted. Intriguingly, this reversed hyperglycemia was sustained
well beyond the treatment period - for at least 4 weeks after
cessation of OA treatment. Along with the correction of
hyperglycemia, elevated urine glucose loss in T2D mice was also
completely reversed and damage to renal structures was markedly
attenuated. Although OA has been reported to lower hypergly-
cemia by counteracting insulin resistance within the period of its
administration [29,30,31], to the best of our knowledge the
sustained reversal of hyperglycemia for such a long duration after
terminating the treatment has not been described before.
Since previous studies reported a hypoglycemic effect in insulin
resistant HF-fed [29,30,31] and db/db mice [18], we first
investigated the effects of OA on hyperglycemia in a T2D model
generated by chronic HF feeding in combination with low doses of
STZ. Chronic HF feeding in rodents is a widely used model of
insulin resistance, associated with lipid accumulation in muscle
and liver [7,32]. However, HF feeding alone is insufficient to cause
diabetes due to the capacity of pancreatic b-cells to increase insulin
secretion in order to compensate for the insulin resistance [33].
Therefore, we administered multiple low doses of STZ to restrict
the ability of pancreatic b-cells to increase insulin secretion,
thereby generating hyperglycemia as previously reported [20,21].
As expected, the combination of HF feeding and low doses of STZ
resulted in marked hyperglycemia with the characteristics of overt
type-2 diabetes, namely, failed compensatory increase in blood
insulin levels with concurrent hypertriglyceridemia and fatty liver.
Compared with CH-fed mice injected with STZ (T1D), HF-fed
mice injected with STZ (T2D) showed significantly more severe
hyperglycemia liver steatosis and visceral adiposity (Table 1).
Oral administration of OA to the T2D mouse model
progressively reduced hyperglycemia to a level similar to that of
normal mice within two weeks. Interestingly, after the termination
of OA treatment the reversed hyperglycemia was retained for the
remaining 4-week period of the study (Fig. 1A). Along with the
reduced blood glucose level, T2D-OA mice also displayed an
improved glucose tolerance at the end of the study when measured
with the total area of glucose under the curve (Fig. 1A, B). While
the hypoglycemic effect of an anti-diabetic compound is expected
during the period of treatment, we are not aware of any other
report showing similarly sustained correction of hyperglycemia
after cessation of drug treatment. This dramatic improvement of
Figure 7. Changes in glucose flux into muscle, adipose tissue and liver 4 weeks after the removal of OA from the diet. An ipGTT (1 g/
kg, ip) using 2-deoxy-D-[1,2-3H] glucose and D-[14C] glucose was performed 4 weeks after the cessation of OA treatment. At the end of the 40-min
ipGTT, tissue samples were freeze-clamped immediately for the measurement of glucose uptake in quadriceps muscle (A) and epididymal fat (B), as
well as the glucose incorporation into lipid (C) and glycogen (D) in the liver. * p,0.05, ** p,0.01 vs. CH, n = 6–12 per group.
doi:10.1371/journal.pone.0042115.g007
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glucose homeostasis for such a long time post-OA treatment is
particularly interesting because sustained control of glycemia is an
important target in the treatment of type-2 diabetes.
Possible mechanisms of the sustained reversal of hyperglycemia
following the treatment of OA were investigated from several
different perspectives. The half-life of OA in the circulation is
reported to be less than 30 min in mice [34], suggesting that the
reversal of hyperglycemia post-OA in the present study is unlikely
to result from a prolonged presence of OA in the circulation. We
therefore first investigated whether OA may induce sustained
improvement of pancreatic b-cell function to increase insulin
secretion, given that acute treatment of OA was previously
reported to enhance insulin secretion in isolated rat b-cells [35].
Such a possibility has been implicated in several previous studies
using a T1D model induced by STZ in CH-fed rodents [17,19].
Conceivably, the sustained reversal of hyperglycemia may be
achieved with a compensatory increase in insulin secretion as
observed in the HF-fed mice in the present study (Table 1) or
improved b-cell function as suggested for incretins [13]. However,
our assessment showed that 2-week treatment of T2D mice with
OA did not increase the number or enhance the function of b -
cells (pancreatic insulin content or insulin secretion of b-cells in
response to glucose stimulation). Furthermore, the blood insulin
profiles during the ipGTT were not different between T2D mice
with/without OA treatment. These results are also consistent with
the inability of OA to lower hyperglycemia in STZ-injected CH-
fed mice in the present study. The reason for the discrepancy of
our results from the previous reports in this T1D rodent model
[17,19] is not clear. However, our findings in T2D and T1D
models are internally consistent and collectively indicate that it is
unlikely that OA exerts its beneficial effects on glycemia through
an improvement in b-cell function.
It has been proposed that the inhibition of SGLT2 (a
transporter for glucose re-absorption in the kidney) can increase
glucose excretion in the urine and thereby reduce hyperglycemia
for the treatment of type-2 diabetes [12,13]. We therefore
examined whether the sustained anti-hyperglycemic effect of OA
was achieved by increasing urine glucose excretion. However, in
contrast to an increase in the glucose excretion through the kidney,
OA treatment significantly reduced the urine glucose level in T2D
mice to the level of CH-fed mice. Furthermore, the diabetic
nephropathy evident in T2D-Veh mice was abolished in T2D
Figure 8. Changes in Akt and FoxO1 in the liver 4 weeks after the removal of OA. Four weeks after the cessation of OA treatment, mice
were sacrificed following a 5–7 hour fast. Liver samples were freeze-clamped and stored at 280uC for subsequent Western blotting analysis.
Representative Western blot images of phosphorylated and total Akt and FoxO1(A). Quantification of p-Akt/GAPDH (B), t-Akt/GAPDH (C), p-/t-Akt (D),
p-FoxO1/GAPDH (E), t-FoxO1/GAPDH (F) and p-/t-FoxO1 (G). * p,0.05 vs. CH; { p,0.05, {{ p,0.01 vs. T2D-Veh, n = 6–8 per group.
doi:10.1371/journal.pone.0042115.g008
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mice treated with OA, as indicated by increased tubular cell
height, and decreased interstitial volume and glomerular turf area.
These results rule out increased urine excretion of glucose as a
mechanism for the reduced glucose level following OA treatment.
These findings are consistent with a recent clinical trial which
demonstrated the beneficial effects of an OA derivative for
nephropathy in type-2 diabetes patients [9]. As OA can improve
renal functions in diabetic mice by inhibiting the formation of
advanced glycation endproducts [17], it is possible that the
reversal of hyperglycemia following the treatment of OA
contributed to the alleviated nephropathy.
The reduced food intake evident in T2D-OA mice during the
period of OA treatment presented another potential mechanism
underlying the sustained reduction in glycemia. Reduced food
intake has been shown to have effects on fasting blood glucose
levels, glucose tolerance and insulin sensitivity in mice and rats
[36,37]. However, it is unknown whether the on glycemia, can be
maintained for days after food intake has normalised. To
investigate possible influences of the different food intake pattern
of T2D-Veh and T2D-OA groups, we conducted a pair-feeding
study with an additional two groups of mice. Despite food intake of
the pair-fed T2D-Veh and T2D-OA groups being matched
throughout the study, T2D-Veh mice maintained significantly
higher glycemia than T2D-OA mice from the second week of OA
treatment and through to the end of the post-treatment period
(Fig. 6A–C). Furthermore, pair-fed T2D-Veh mice were not as
glucose tolerant as T2D-OA mice as evidenced by an ipGTT
performed at the end of the study (Fig. 6D, E). These data indicate
that the effect of OA to improve glucose homeostasis in diabetic
mice does not rely on its effect to reduce food intake. In support of
this interpretation, a recent study has demonstrated that an OA
analogue can lower blood glucose in both HF-fed and db/db mice
without affecting food intake [18].
Several studies have shown that triterpenoids, including OA,
can reverse insulin resistance and glucose intolerance during the
treatment period [18,29,30,38]. The present study similarly
observed that T2D-OA mice displayed significantly lower plasma
glucose levels during ipGTT. Since OA treatment attenuates the
glucose intolerance with similar blood insulin levels as T2D-Veh
mice, the improved glucose tolerance and glycemia in T2D-OA
mice is probably due to improved insulin sensitivity of the
peripheral tissues.
Insulin resistance is closely related with increased accumulation
of lipids in peripheral tissues [39] and a reduction in lipid content
in these tissues is an effective means to improve insulin sensitivity
[7]. The reversal of insulin resistance and glucose intolerance
during OA treatment has been associated with a reduction of lipid
accumulation in muscle and liver [18,29,30,38]. As triterpenoids
can acutely activate AMPK and promote fat oxidation [14], one
plausible mechanism of the sustained efficacy to reduce hypergly-
cemia in the present study could conceivably be due to improved
insulin action as a result of reduced lipid accumulation in muscle
and liver. Such a mechanism has been demonstrated with
berberine [40], and Abbot compound A [41] during the period
of treatment. To investigate if OA improves insulin sensitivity
through a similar mechanism, we measured the triglyceride levels
Figure 9. Changes in PEPCK and G6Pase expression in the liver 4 weeks after the removal of OA. Four weeks after the cessation of OA
treatment, mice were sacrificed following a 5–7 hour fast. Liver samples were freeze-clamped and stored for subsequent analysis of PEPCK and
G6Pase RNA expression. The expression levels of PEPCK and G6Pase mRNA relative to 18S (A and B). Correlation of p-Akt/GAPDH and FoxO1/GAPDH
with G6Pase mRNA expression in T2D-Veh and T2D-OA groups by a best-fit regression analysis (C). * p,0.05 vs. CH, n = 6–8 per group. Proposed
mechanism for the sustained reduction in hyperglycemia following the treatment of OA (D).
doi:10.1371/journal.pone.0042115.g009
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in plasma and liver because a reduction in hepatic steatosis is able
to normalize glycemia in type-2 diabetes [42]. Indeed, associated
with the corrected glycemia, the triglyceride levels in plasma and
liver were reduced to almost the normal levels of CH-mice during
the period of OA administration. These results are similar to those
recently reported in db/db mice within the treatment duration of
an OA analogue, along with increased AMPK activity [18].
However, as the efficacy of OA on triglyceride levels in plasma and
liver did not persist after cessation of OA treatment, the sustained
reduction in glycemia is likely to involve alternative/additional
mechanisms rather than the improvement in dyslipidemia and
hepatic steatosis alone.
Glucose uptake into skeletal muscle and hepatic production of
glucose are two major metabolic pathways responsible for glucose
homeostasis. With the use of [3H]-2DG and D-[14C] glucose
tracers, we demonstrated a reduction of glucose uptake into
muscle and adipose tissue in T2D-Veh mice and there was no
improvement of glucose uptake in these two tissues in T2D-OA
mice. The lack of an effect of OA upon glucose uptake into muscle
and liver indicated that the liver may be the major site for the
sustained improvement of glycemia after the treatment with OA.
To investigate the possible role of the liver, we first assessed
glucose influx into this organ, but found no improvement in
glucose incorporation into either glycogen or triglyceride (note that
measurement of glucose uptake with 2DG in the liver is not valid).
We next examined indicators of hepatic glucose production
(efflux). Interestingly, we found that the insulin signaling trans-
duction (indicated by the phosphorylation of Akt and FoxO1)
regulating gluconeogenesis was significantly improved in OA
treated mice. FoxO1 is a key transcription factor regulating
hepatic gluconeogenesis. The phosphorylation of FoxO1 by Akt
leads to its expulsion from the nucleus for degradation [28,43]. A
recent study has indicated that the Akt-FoxO1 signaling plays a
key role in controlling the expression of G6Pase [43]. Indeed, we
found a trend of reduced expression of G6Pase (p = 0.09).
Importantly the suppressed expression of G6Pase was significantly
correlated with increased phosphorylation of Akt and FoxO1 (both
p,0.05). As G6Pase is the gate-keeping enzyme for hepatic
glucose production, our data indicate that its down-regulation
induced by the Akt/FoxO1 signaling pathway is a likely
mechanism for the sustained improvement of glycemia after the
treatment with OA (Fig. 9E).
In summary, the present study demonstrated a sustained effect
of OA to reverse hyperglycemia in T2D mice induced by HF-
feeding and STZ. Our data indicate that OA, a triterpenoid
abundantly present in natural products, may be a potential drug
for the sustained control of hyperglycemia in type-2 diabetes and
related kidney complications independent of lipid metabolism,
insulin secretion and glucose disappearance into muscle and fat
tissue. Furthermore, our data suggest that the sustained improve-
ment of glucose homeostasis is due, at least in part, to a
suppression of gluconeogenesis in the liver mediated by the Akt/
FoxO1 axis. The findings in our study also provide a proof of
concept for the potential of triterpenoids as a promising source to
explore new drugs for the long-term control or cure of
hyperglycemia and diabetic kidney complications.
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